524663 — Bharat Immunologicals and Biologicals Income Statement
0.000.00%
Last trade - 00:00- IN₹1.01bn
- IN₹1.68bn
- IN₹446.09m
Annual income statement for Bharat Immunologicals and Biologicals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 836 | 668 | 853 | 784 | 446 |
| Cost of Revenue | |||||
| Gross Profit | 31.4 | -4.99 | -103 | 49.1 | -97 |
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 932 | 775 | 1,064 | 836 | 632 |
| Operating Profit | -95.9 | -106 | -211 | -52 | -186 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -73.7 | -142 | -242 | -96.9 | -229 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -57.9 | -102 | -181 | -87.5 | -171 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -57.9 | -102 | -181 | -87.5 | -171 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -57.9 | -102 | -181 | -87.5 | -171 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 |